NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Cerenome, Inc. (CNSY) Stock Analysis

Cerenome, Inc. (CNSY) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CNSY

$2.76

−$0.22 (−7.38%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CNSY with… →

CNSY Key Statistics

As of Sep 4, 2026
Trading
Open
$2.89
Previous Close
$2.98
Day's Range
2.74–3.00
52-Week Range
2.62–23.50
Volume
35.30K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.39
Valuation
Market Cap
$20.91M
P/E Ratio
1.01
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
2.45
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.97
EPS (ttm)Profit attributable to each share over the last twelve months.
2.72
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$22.39M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
7.59M
1-Year Return
−75.47%
Dividend and dates
Avg Volume
135.80K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CNSY Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−78.35%
2025−55.65%
2024−34.29%
2023−63.54%
2022−69.52%
2021−48.02%
2020−15.83%
2019−83.45%
2018−90.33%
2017−80.13%
2016 (partial year)−26.70%

As of September 4, 2026.

CNSY Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$22.39M—
2024$0.00−$12.98M—
2023$0.00−$13.32M—
2022$0.00−$20.28M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$15.30M−$22.39M—
2024$0.00—−$14.70M−$12.98M—
2023$0.00—−$13.32M−$13.32M—
2022$0.00—−$19.71M−$20.28M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CNSY Valuation vs Biotechnology Median

Median of 656 stocks
MetricCNSYBiotechnology medianvs median
P/E1.0112.570.1x the median
P/S ratio4.9715.260.3x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Cerenome, Inc. (CNSY) is capitalised at $20.91M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 28 employees.

Over the past 52 weeks the price has ranged from $2.62 to $23.50. CNSY last closed at $2.76 on September 4, 2026. That is −$0.22 (−7.38%) against the previous close. The latest close sits 5.34% above that 52-week low.

Financial Health

In fiscal 2025, Cerenome, Inc. reported revenue of $0.00. The same year closed with a net loss of $22.39M. The reported profit margin is 0%. Earnings per share on a trailing basis come to 2.72.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 1.01. That is 0.1 times the Biotechnology median of 12.57. The PEG ratio, which sets the P/E against expected earnings growth, reads 2.45. Measured against sales, the shares trade at 4.97 times revenue. On price-to-sales that is 0.3 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is −75.47%. Measured over 10 years, that is −69.41% a year compounded. Beta against the wider market is reported at 1.39. Annualized volatility over the trailing 10 years is 184.62%.

Growth & Income

No dividend is on file for CNSY.

Across the complete calendar years on file, 2020 returned −15.83% and 2018 returned −90.33%. Of the 9 complete calendar years on file, 0 finished higher. 2026 is still running; the price is −78.35% year to date.

Peer Comparison

Cerenome, Inc. (CNSY) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Cerenome, Inc. CNSY $20.91M 1.0
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Cerenome, Inc. trades at a P/E of 1.0.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Cerenome, Inc.

Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers, by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas, as well as develops a data analytics and artificial intelligence platform to integrate diverse data sets into actionable insights that support precision oncology, therapeutic development, and clinical decision-making. The company was formerly known as Plus Therapeutics, Inc. and changed its name to Cerenome, Inc. in August 2026. Cerenome, Inc. was founded in 1996 and is headquartered in Houston, Texas.

Visit website →